Zhejiang Nhu Co Ltd
SZSE:002001
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (11.4), the stock would be worth ¥25.87 (26% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.4 | ¥34.96 |
0%
|
| 3-Year Average | 11.4 | ¥25.87 |
-26%
|
| 5-Year Average | 15.9 | ¥36.08 |
+3%
|
| Industry Average | 30.7 | ¥69.79 |
+100%
|
| Country Average | 28.8 | ¥65.47 |
+87%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
106.6B CNY | 15.4 | 16.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 154.8 | 43.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.3 | 26.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.6 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 12 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Zhejiang Nhu Co Ltd
Glance View
Zhejiang Nhu Co Ltd. began its journey in the dynamic world of pharmaceuticals and chemicals, carving a niche for itself in a highly competitive market. Established in Zhejiang Province, China, the company quickly established a reputation for producing high-quality vitamins and nutraceutical ingredients. The precision and reliability of their manufacturing processes cater to various industries, from animal nutrition to human healthcare, standing as a testament to their commitment to excellence. Their state-of-the-art facilities and rigorous quality control have allowed them to expand their reach beyond domestic borders, tapping into the global market and serving an international clientele. At the heart of Zhejiang Nhu's business model is its ability to leverage cost-effective manufacturing to provide competitively priced products without compromising on quality. This approach not only ensures strong demand for their ingredients but also positions the company favorably against global competitors. By efficiently scaling their operations and investing in research and development, Zhejiang Nhu continuously enhances its product portfolio, thus creating multiple revenue streams. The company's strategic investments in technological innovation have paved the way for it to remain relevant and competitive, ensuring sustainable growth in an ever-evolving industry landscape.
